**Supplementary Table S1. Clinical characteristics of treatment-naïve CHB patients**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Total** | **Undetectable HBV DNA** | **Detectable HBV DNA** | ***P*-value** |
| **No. of patients, n (%)** | 6039 (100.00) | 1021 (16.91) | 5018 (83.09) |  |
| **Age, n (%)** |  |  |  | <0.001 |
| **≤ 30 years** | 1411 (23.36) | 108 (10.58) | 1303 (25.97) |  |
|  **30 - 59 years** | 4083 (67.61) | 757 (74.14) | 3326 (66.28) |  |
|  **≥ 60 years** | 545 (9.02) | 156 (15.28) | 389 (7.75) |  |
| **Male, n (%)** | 3770 (62.43) | 618 (60.53) | 3152 (62.81) | 0.181 |
| **HBeAg Positive, n (%)** | 1802 (29.84) | 217 (21.25) | 1585 (31.59) | <0.001 |
| **ALT, U/L** | 40.00 (24.00, 79.00) | 29.00 (19.00, 51.00) | 42.00 (25.00, 85.00) | <0.001 |
| **AST, U/L** | 32.20 (23.00, 58.60) | 29.80 (20.80, 53.70) | 33.00 (23.93, 61.00) | <0.001 |
| **PLT, ×109/L** | 180.71 ± 73.13 | 163.55 ± 77.88 | 184.20 ± 71.63 | <0.001 |
| **ALB, g/L** | 43.12 ± 8.84 | 42.94 ± 17.17 | 43.15 ± 5.73 | 0.699 |
| **TBiL, μmol/L** | 15.00 (11.10, 21.90) | 19.00 (12.10, 26.00) | 14.60 (11.00, 20.20) | <0.001 |
| **HBV-DNA, n (%)** |  |  |  | <0.001 |
| **< 2000 IU/mL** | 1531 (25.35) | 1021 (100.00) | 510 (10.16) |  |
| **2000-19999 IU/mL** | 1174 (19.44) | 0 (0) | 1174 (23.40) |  |
| **≥ 20000 IU/mL** | 3334 (55.21) | 0 (0) | 3334 (66.44) |  |
| **APRI WHO 2024 Criteria** |  |  |  |  |
|  **> 0.5, n (%)** | 2901 (48.04) | 526 (51.52) | 2375 (47.33) | 0.016 |
| **> 1.0, n (%)** | 1633 (27.04) | 322 (31.54) | 1311 (26.13) | <0.001 |
| **APRI WHO 2015 Criteria** |  |  |  |  |
| **> 1.5, n (%)** | 1124 (18.61) | 211(20.67) | 913 (18.19) | 0.071 |
| **> 2.0, n (%)** | 846 (14.01) | 156 (15.28) | 690 (13.75) | 0.217 |
| **FIB-4 > 3.25, n (%)** | 1009 (16.71) | 288 (28.21) | 721 (14.37) | <0.001 |